SGLT2 Inhibitor and GLP‐1 Receptor Agonist Prescriptions in Newly Diagnosed Type 2 Diabetes Patients With Cardiorenal Risks: A Cross‐Sectional Study
Journal of Diabetes Research · 2025
DOI: 10.1155/jdr/6656982 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Diabetes Research, 2025. Verfasst von Frank Müller und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Family Medicine, College of Human Medicine, Michigan State University, Grand Rapids, Michigan, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
The aim of this study is to evaluate the real‐world prescribing patterns of SGLT2 inhibitors and GLP‐1 receptor agonists (GLP‐1RA) in patients with newly diagnosed Type 2 diabetes (T2DM), particularly among those with high cardiovascular risks or chronic kidney disease, and to identify demographic, clinical, and system‐level factors associated with receiving these medications. Materials and Methods This cross‐sectional study analyzed electronic medical records (EMRs) of patients with newly diagnosed T2DM from 60 primary care clinics in West Michigan between April 2021 and January 2023. We assessed the documented prescription rates of SGLT2 inhibitors and GLP‐1RAs within 3 months of diagnosis based on EMRs, particularly in high‐risk subgroups.
Results
Overall, 19.9% of n = 5783 patients with newly diagnosed T2DM had either an SGLT2 inhibitor or GLP‐1RA prescribed. Prescription rates for these agents were 20.0% for patients with chronic ischemic heart disease and 19.3% for those with impaired kidney function. In adjusted analyses, higher BMI (aOR 2.92 for BMI > 40 kg/m 2 , 95% CI 1.58–5.42, ref BMI < 24 kg/m 2 ), hyperlipidemia (aOR 1.89, 95% CI 1.28–2.79), chronic ischemic heart disease (aOR 1.55, 95% CI 1.11–2.18), and higher HbA1c (aOR 1.32 per 1% increase, 95% CI 1.22–1.42) were associated with higher odds of receiving prescription of these medications.
Conclusions
Despite guideline recommendations, SGLT2 inhibitors and GLP‐1RAs are prescribed to only a minority of patients with newly diagnosed T2DM, even among those with clear indications. Efforts to improve guideline‐adherent care in primary care settings are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Family Medicine, College of Human Medicine, Michigan State University, Grand Rapids, Michigan, USA.
- Corewell Health Family Medicine Residency Center, Corewell Health, Grand Rapids, Michigan, USA.
- Department of General Practice, University Medical Center Göttingen, Göttingen, Germany.
- Department of Family Medicine, College of Human Medicine, Michigan State University, East Lansing, Michigan, USA.
ORCID-Profile: Frank Müller, Omayma Alshaarawy, Harland T Holman
Förderung
- NIDDK NIH HHS
Zitieren
APA
Müller, F., Bouthillier, M. J., Alshaarawy, O., Azhary, H., & Holman, H. T. (2025). SGLT2 Inhibitor and GLP‐1 Receptor Agonist Prescriptions in Newly Diagnosed Type 2 Diabetes Patients With Cardiorenal Risks: A Cross‐Sectional Study. Journal of Diabetes Research. https://doi.org/10.1155/jdr/6656982
Vancouver
Müller F, Bouthillier MJ, Alshaarawy O, Azhary H, Holman HT. SGLT2 Inhibitor and GLP‐1 Receptor Agonist Prescriptions in Newly Diagnosed Type 2 Diabetes Patients With Cardiorenal Risks: A Cross‐Sectional Study. Journal of Diabetes Research. 2025. doi:10.1155/jdr/6656982
BibTeX
@article{Mller2025,
author = {Müller, Frank and Bouthillier, Michael J and Alshaarawy, Omayma and Azhary, Hend and Holman, Harland T},
title = {SGLT2 Inhibitor and GLP‐1 Receptor Agonist Prescriptions in Newly Diagnosed Type 2 Diabetes Patients With Cardiorenal Risks: A Cross‐Sectional Study},
journal = {Journal of Diabetes Research},
year = {2025},
doi = {10.1155/jdr/6656982}
}
EUVIMED